BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 20933505)

  • 1. FOXO1 is a direct target of EWS-Fli1 oncogenic fusion protein in Ewing's sarcoma cells.
    Yang L; Hu HM; Zielinska-Kwiatkowska A; Chansky HA
    Biochem Biophys Res Commun; 2010 Nov; 402(1):129-34. PubMed ID: 20933505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suppression of FOXO1 is responsible for a growth regulatory repressive transcriptional sub-signature of EWS-FLI1 in Ewing sarcoma.
    Niedan S; Kauer M; Aryee DN; Kofler R; Schwentner R; Meier A; Pötschger U; Kontny U; Kovar H
    Oncogene; 2014 Jul; 33(30):3927-38. PubMed ID: 23995784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A zebrafish transgenic model of Ewing's sarcoma reveals conserved mediators of EWS-FLI1 tumorigenesis.
    Leacock SW; Basse AN; Chandler GL; Kirk AM; Rakheja D; Amatruda JF
    Dis Model Mech; 2012 Jan; 5(1):95-106. PubMed ID: 21979944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hsa-mir-145 is the top EWS-FLI1-repressed microRNA involved in a positive feedback loop in Ewing's sarcoma.
    Ban J; Jug G; Mestdagh P; Schwentner R; Kauer M; Aryee DN; Schaefer KL; Nakatani F; Scotlandi K; Reiter M; Strunk D; Speleman F; Vandesompele J; Kovar H
    Oncogene; 2011 May; 30(18):2173-80. PubMed ID: 21217773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EWS/FLI and its downstream target NR0B1 interact directly to modulate transcription and oncogenesis in Ewing's sarcoma.
    Kinsey M; Smith R; Iyer AK; McCabe ER; Lessnick SL
    Cancer Res; 2009 Dec; 69(23):9047-55. PubMed ID: 19920188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Promiscuous partnerships in Ewing's sarcoma.
    Sankar S; Lessnick SL
    Cancer Genet; 2011 Jul; 204(7):351-65. PubMed ID: 21872822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EWS-FLI1 in Ewing's sarcoma: real targets and collateral damage.
    Ban J; Siligan C; Kreppel M; Aryee D; Kovar H
    Adv Exp Med Biol; 2006; 587():41-52. PubMed ID: 17163154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ewing's sarcoma oncoprotein EWS-FLI1: the perfect target without a therapeutic agent.
    Uren A; Toretsky JA
    Future Oncol; 2005 Aug; 1(4):521-8. PubMed ID: 16556028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EWS/FLI1 suppresses retinoblastoma protein function and senescence in Ewing's sarcoma cells.
    Hu HM; Zielinska-Kwiatkowska A; Munro K; Wilcox J; Wu DY; Yang L; Chansky HA
    J Orthop Res; 2008 Jun; 26(6):886-93. PubMed ID: 18271016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of p21WAF1/CIP1 as a direct target of EWS-Fli1 oncogenic fusion protein.
    Nakatani F; Tanaka K; Sakimura R; Matsumoto Y; Matsunobu T; Li X; Hanada M; Okada T; Iwamoto Y
    J Biol Chem; 2003 Apr; 278(17):15105-15. PubMed ID: 12560328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A molecular function map of Ewing's sarcoma.
    Kauer M; Ban J; Kofler R; Walker B; Davis S; Meltzer P; Kovar H
    PLoS One; 2009; 4(4):e5415. PubMed ID: 19404404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The evaluation of CD99 immunoreactivity and EWS/FLI1 translocation by fluorescence in situ hybridization in central PNETs and Ewing's sarcoma family of tumors.
    Vural C; Uluoğlu O; Akyürek N; Oğuz A; Karadeniz C
    Pathol Oncol Res; 2011 Sep; 17(3):619-25. PubMed ID: 21267687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NR0B1 is required for the oncogenic phenotype mediated by EWS/FLI in Ewing's sarcoma.
    Kinsey M; Smith R; Lessnick SL
    Mol Cancer Res; 2006 Nov; 4(11):851-9. PubMed ID: 17114343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncogenic partnerships: EWS-FLI1 protein interactions initiate key pathways of Ewing's sarcoma.
    Erkizan HV; Uversky VN; Toretsky JA
    Clin Cancer Res; 2010 Aug; 16(16):4077-83. PubMed ID: 20547696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EWS-Fli1 up-regulates expression of the Aurora A and Aurora B kinases.
    Wakahara K; Ohno T; Kimura M; Masuda T; Nozawa S; Dohjima T; Yamamoto T; Nagano A; Kawai G; Matsuhashi A; Saitoh M; Takigami I; Okano Y; Shimizu K
    Mol Cancer Res; 2008 Dec; 6(12):1937-45. PubMed ID: 19074838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impairment of p53 acetylation by EWS-Fli1 chimeric protein in Ewing family tumors.
    Li Y; Li X; Fan G; Fukushi J; Matsumoto Y; Iwamoto Y; Zhu Y
    Cancer Lett; 2012 Jul; 320(1):14-22. PubMed ID: 22266186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transactivation of cyclin E gene by EWS-Fli1 and antitumor effects of cyclin dependent kinase inhibitor on Ewing's family tumor cells.
    Li X; Tanaka K; Nakatani F; Matsunobu T; Sakimura R; Hanada M; Okada T; Nakamura T; Iwamoto Y
    Int J Cancer; 2005 Sep; 116(3):385-94. PubMed ID: 15818598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EWS-FLI1 and Menin Converge to Regulate ATF4 Activity in Ewing Sarcoma.
    Jiménez JA; Apfelbaum AA; Hawkins AG; Svoboda LK; Kumar A; Ruiz RO; Garcia AX; Haarer E; Nwosu ZC; Bradin J; Purohit T; Chen D; Cierpicki T; Grembecka J; Lyssiotis CA; Lawlor ER
    Mol Cancer Res; 2021 Jul; 19(7):1182-1195. PubMed ID: 33741715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High ALDH activity identifies chemotherapy-resistant Ewing's sarcoma stem cells that retain sensitivity to EWS-FLI1 inhibition.
    Awad O; Yustein JT; Shah P; Gul N; Katuri V; O'Neill A; Kong Y; Brown ML; Toretsky JA; Loeb DM
    PLoS One; 2010 Nov; 5(11):e13943. PubMed ID: 21085683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single-chain antibodies to the EWS NH(2) terminus structurally discriminate between intact and chimeric EWS in Ewing's sarcoma and interfere with the transcriptional activity of EWS in vivo.
    Aryee DN; Kreppel M; Bachmaier R; Uren A; Muehlbacher K; Wagner S; Breiteneder H; Ban J; Toretsky JA; Kovar H
    Cancer Res; 2006 Oct; 66(20):9862-9. PubMed ID: 17047047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.